

The Medical Letter[®]

on Drugs and Therapeutics

Volume 67

August 18, 2025

ISSUE No.
1735

IN THIS ISSUE

In Brief: A New Donanemab (*Kisunla*) Dosing Regimen for Alzheimer's Diseasep 134

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 67 (Issue 1735)

August 18, 2025

Take CME Exams

IN BRIEF

A New Donanemab (*Kisunla*) Dosing Regimen for Alzheimer's Disease

The FDA has approved a new titration regimen for donanemab (*Kisunla* – Lilly),¹ an IV amyloid beta-directed monoclonal antibody indicated for treatment of Alzheimer's disease. The new regimen is intended to reduce the risk of serious amyloid-related imaging abnormalities (ARIA) associated with use of the drug.

CLINICAL STUDIES – FDA approval of the new titration regimen was based on the results of a double-blind trial (TRAILBLAZER-ALZ 6) in 843 patients with early symptomatic Alzheimer's disease who were randomized to receive standard donanemab dosing or one of three alternative dosing regimens (modified titration, dose skipping, or Cmax). The frequency of ARIA with edema/effusions (ARIA-E) at 24 weeks was significantly lower with modified titration dosing than with standard dosing (13.7% vs 23.7%), but the frequency of ARIA with hemorrhages/hemosiderin deposition (ARIA-H) was not (20.3% vs 25.1%). Amyloid reduction from baseline was similar in the modified titration and standard dosing groups (-56.3% vs -58.8%). Results were maintained at 52 weeks.²

ADVERSE EFFECTS – The most common adverse effects of donanemab in clinical trials have been ARIA-E and ARIA-H. The risk of ARIA is greater in patients who are APOE ε4 homozygotes (~15% of patients with Alzheimer's disease).

Headache and infusion-related reactions also commonly occur in patients taking donanemab. Hypersensitivity reactions have occurred. Intestinal obstruction and perforation have been reported rarely.

DOSAGE, ADMINISTRATION, AND COST – Donanemab is administered by intravenous infusion over 30 minutes every 4 weeks. The recommended dosage is now 350 mg for infusion 1, 700 mg for infusion 2, 1050 mg for infusion 3, and 1400 mg for infusion 4 and every 4 weeks thereafter. (The previous dosing regimen was 700 mg every 4 weeks for 3 doses, then 1400 mg every four weeks.) The total amount of donanemab in the titration regimen remains the same. The wholesale acquisition cost (WAC) for a 1400-mg dose of *Kisunla* is about \$2800.³ ■

1. Donanemab (*Kisunla*) for Alzheimer's disease. *Med Lett Drugs Ther* 2024; 66:129.
2. H Wang et al. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. *Alzheimers Dement* 2025; 21:e70062.
3. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. July 5, 2025. Reprinted with permission by First Databank, Inc. All rights reserved. ©2025. www.fdbhealth.com/policies/drug-pricing-policy.

Follow us



PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Dartmouth Hitchcock Medical Center; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
2 Madison Ave, Ste 211
Larchmont, NY 10538
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year – \$179; \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints – \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:



Copyright 2025. ISSN 1523-2859

The
Medical
Letter